Articles from Medicines360

SAN FRANCISCO and CAPE TOWN, South Africa, April 22, 2026 (GLOBE NEWSWIRE) -- Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine device (IUD), marking a significant step forward in access to long‑acting reversible contraception (LARC) and the treatment of heavy menstrual bleeding (HMB). AVIBELA, developed by Medicines360, is a quality-assured hormonal IUD that is more than 99% effective at preventing pregnancy for up to six years of use (the approved duration of use in South Africa).i

Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide.

SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical device designed to prevent severe perineal tears during birth, from Fruits of Labor, Inc. PeriPeach will now advance through the 360 Innovation Hub, Medicines360’s platform for accelerating transformative women’s health solutions.

Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360

Medicines360 and DKT WomanCare are joining forces to increase availability and use of AVIBELA, an affordable, effective, long-acting hormonal IUD developed by Medicines360, across Africa, South and Southeast Asia, Central America, and the Caribbean.

David brings over 30 years of experience in the public health and healthcare sectors to Medicines360